Drivers of Depression and Anxiety in US Non-Segmental Vitiligo Patients

Author(s)

Mohit B1, Fleming S1, Brady J1, Marwaha S2, Austin J2, Quinones E2, Middleton-Dalby C2
1Merck & Co., Rahway, NJ, USA, 2Adelphi Real World, Bollington, Cheshire, UK

Presentation Documents

OBJECTIVES: Vitiligo is an autoimmune skin depigmentation disorder which can be detrimental to patients’ psychosocial health. This study evaluates factors that drive depression and anxiety in non-segmental vitiligo (NSV) patients, beyond clinical manifestations of the disease.

METHODS: Data were drawn from the Adelphi Vitiligo Disease Specific ProgrammeTM, a cross-sectional survey of physicians and their adult and adolescent NSV patients in the US conducted between October 2021 and April 2022. Physicians reported patient demographics, clinical characteristics, and treatment history. Patients provided information on feelings about their vitiligo and its impact on their lives, including the Hospital Anxiety and Depression Scale (HADS) and Vitiligo Noticeability Scale (VNS). Data were analysed using elastic net regressions, an extension of LASSO and ridge regression which uses regularization to model a large number of predictor variables.

RESULTS: Analysis included 112 patients (54.56% female; mean age = 35 [sd=33]) with NSV from the US with complete data for the 87 variables input into the elastic net models. The key drivers of worsening HADS depression were: VNS reported as a lot less noticeable by patient (β = 0.599), experiencing bullying in everyday life due to their vitiligo (β = 0.402), feeling isolated due to their vitiligo (β = 0.389), and vitiligo affecting their face (β = 0.315). Key drivers of the HADS anxiety domain were: VNS reported as a lot less noticeable (β = 1.305), experiencing bullying in everyday life due to vitiligo (β = 0.432), frustration with treatment options (β = 0.298), feeling isolated due to vitiligo (β = 0.260), and vitiligo affecting their face (β = 0.177).

CONCLUSIONS: Feelings of societal isolation and stigmatization due to NSV are expectedly strong indicators of depression and anxiety, more unexpectedly we also see improvement in vitiligo noticeability as an indicator. This highlights the pervasive effect NSV can have on patients despite clinical improvement.

Conference/Value in Health Info

2024-05, ISPOR 2024, Atlanta, GA, USA

Value in Health, Volume 27, Issue 6, S1 (June 2024)

Code

PCR169

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Mental Health (including addition), Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×